Antenatal factors modulate hearing screen failure risk in preterm infants
| Autor: | Alexander G Agthe, Chen-Chih J. Sun, Christina L. Cifra, Rose M. Viscardi, Jocelyn C Leung |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Hearing loss Infant Premature Diseases Logistic regression 03 medical and health sciences 0302 clinical medicine Neonatal Screening Pregnancy Risk Factors 030225 pediatrics Ductus arteriosus otorhinolaryngologic diseases medicine Humans Infant Very Low Birth Weight 030212 general & internal medicine Prospective Studies Risk factor Hearing Loss Retrospective Studies Fetus business.industry Hearing Tests Infant Newborn Obstetrics and Gynecology Retrospective cohort study General Medicine medicine.disease Pregnancy Complications medicine.anatomical_structure Pediatrics Perinatology and Child Health Cohort Cytokines Female medicine.symptom Vasculitis business Infant Premature |
| Zdroj: | Archives of disease in childhood. Fetal and neonatal edition. 101(1) |
| ISSN: | 1468-2052 |
| Popis: | The objective of this study was to characterise the effects of antenatal inflammatory factors and maternal therapies on neonatal hearing screen outcomes in very low birthweight infants.We conducted a retrospective study of a cohort of infants33 weeks' gestational age and1501 g birth weight prospectively enrolled between 1999 and 2003 for whom placental pathology, cord blood interleukin (IL) 6, IL-1ß, tumour necrosis factor-α and neonatal hearing screen results were available.Of 289 infants with documented hearing screen results, 244 (84%) passed and 45 (16%) failed the hearing screen (unilateral, N=25 (56%); bilateral, N=20 (44%)). In the final logistic model, the fetal inflammatory response syndrome defined as the presence of fetal vasculitis and/or cord serum IL-618.2 pg/mL was the factor with greatest risk for hearing screen failure (OR 3.62, 95% CI 1.38 to 9.5). A patent ductus arteriosus treated with indomethacin significantly increased the risk (OR 3.3, 95% CI 1.3 to 8.26), while combined maternal steroid and magnesium sulfate exposure (0.37, 95% CI 0.11 to 0.81) reduced the risk for hearing screen failure.Intrauterine infection with a fetal inflammatory response is a risk factor for neonatal hearing loss while maternal therapies significantly reduced the risk of neonatal hearing loss in very low birthweight infants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|